mitochondrial biogenesis is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-01-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
The CUX1 gene Alternatively Spliced Product was first reported in 1997. The CUX1 gene has up to 33 exons. CASP mRNA includes exons 1 through 14 and 25 through 33. The human CASP protein is predicted to contain 678 amino acids, of which 400 are shared with CUTL1. CASP protein is approximately 80 kD. It lacks the DNA binding region of CUTL1, but instead contains a trans-membrane domain that allows it to insert into lipid bilayers. It has been localized to the Golgi apparatus. CASP has been reported to be part of a complex with Golgin 84 that tethers COPI vesicles and is important for retrograde transport in the Golgi and between the Golgi and endoplasmic reticulum. The targeting of vesicles involves tethers and SNAREs.
Adjacent to the museum is Sir Frederick G. Banting Square, a garden with several information plaques, and three main attractions. Two of the attractions, a full-sized sculpture of Banting writing his life-altering idea down, and the Flame of Hope, were unveiled by Her Majesty Queen Elizabeth The Queen Mother. The Flame of Hope, symbolizing the hope for a final cure for diabetes, was kindled by Her Majesty during her visit. The third attraction is the globe sculpture, which was added more recently in 2010. It represents Canada's gift to the world, and embraces Banting House's visitors from abroad, with the names of every country listed on it.
== Metabolism and derivatives == 14-Hydroxycaryophyllene oxide (C15H24O2) was isolated from the urine of rabbits treated with (−)-caryophyllene (C15H24). The X-ray crystal structure of 14-hydroxycaryophyllene (as its acetate derivative) has been reported. The metabolism of caryophyllene progresses through (−)-caryophyllene oxide (C15H24O) since the latter compound also afforded 14-hydroxycaryophyllene (C15H24O) as a metabolite.
Biocompatible Excludes unwanted cell types Allows tissue integration Creates and maintains space Is easy to trim and place Several surgical techniques via GBR have been proposed regarding the tri-dimensional bone reconstruction of the severely resorbed maxilla, using different types of bone substitutes that have regenerative, osseoinductive or osseoconductive properties which is then packed into the bony defect and covered by resorbable membranes. In cases where augmentation materials used are autografts (tissue transfer from same person) or allografts (tissue from genetically dissimilar members of same species) the bone density is quite low and resorption of the grafted site in these cases can reach up to 30% of original volume. Other materials available xenografts (tissue donor from another species) and autogenous bone. For higher predictability, nonresorbable titanium-reinforced d-polytetrafluoroethylene (d-PTFE) membranes—as a barrier against the migration of epithelial cells within the grafted site—are recommended. In patients with systemic problems interdisciplinary collaboration is indicated to adjust therapy background so that it does not adversely affect implanto-prosthetic treatment. Current treatments for destructive periodontal disease are not able to restore damaged bone and connective tissue support for teeth (infra-bony defects). Currently there are two types of barrier membranes available: resorbable and non-resorbable.
Sources: en.wikipedia.org
Exactly one month after the declaration was issued, a large-scale celebration took place at the Royal Opera House – speeches were given by leading Zionists as well as members of the British administration including Sykes and Cecil. From 1918 until the Second World War, Jews in Mandatory Palestine celebrated Balfour Day as an annual national holiday on 2 November. The celebrations included ceremonies in schools and other public institutions and festive articles in the Hebrew press. In August 1919 Balfour approved Weizmann's request to name the first post-war settlement in Mandatory Palestine, "Balfouria", in his honour. It was intended to be a model settlement for future American Jewish activity in Palestine. Herbert Samuel, the Zionist MP whose 1915 memorandum had framed the start of discussions in the British Cabinet, was asked by Lloyd George on 24 April 1920 to act as the first civil governor of British Palestine, replacing the previous military administration that had ruled the area since the war. This decision reflected a clear pro-Zionist stance by the British government. Shortly after beginning the role in July 1920, he was invited to read the haftarah from Isaiah 40 at the Hurva Synagogue in Jerusalem, which, according to his memoirs, led the congregation of older settlers to feel that the "fulfilment of ancient prophecy might at last be at hand".
==== Sulfur and lightning ==== Sulfur’s role as a symbol of divine wrath and punishment may come from its association with lightning. For centuries, lightning was thought to cause a sulfur smell when it struck, and was therefore linked with it, including in religious contexts. In the 12th century, the Byzantine scholar John Tzetzes discussed the different associations around the word theion in his Chiliades, mentioning different meanings such as sulfur, incense (which he links to the breath of the immortals) and thunder, as well as it referring to "bewildering" and "amazing" things, the stars, souls, and angels. He explains that thunder is divine fire, and that it gives off a strong smell resembling sulfur. Lightning being sulfurous is a very ancient belief, mentioned by ancient Roman authors and present in the works of Homer, where descriptions of the divine lightning of Zeus mention sulfur several times (in the Iliad, it strikes in front of the horses of Diomedes, causing a smell of sulfur and flames, at another point, Hector is compared to an oak uprooted by Zeus' lightning, smelling of sulfur, while in the Odyssey, it strikes a ship, filling it with sulfurous smoke). The 18th century theologian Jonathan Edwards considered lightning to be "a string of brimstone". Lightning does not actually contain sulfur or produce sulfur odorants. Ozone would later be identified, in the 19th century, as the element behind the smell of lightning, but even then, people unfamiliar with ozone were said to still commonly misidentify the smell as brimstone.
== External links == The MEROPS online database for peptidases and their inhibitors: A02.001 Archived 2005-01-23 at the Wayback Machine Proteopedia HIV-1_protease - the HIV-1 protease structure in interactive 3D. Proteopedia Flaps_Morph_for_HIV_Protease - Animation of the flaps opening and closing based on X-ray crystal structures. HIV-1+Protease at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
==== Haiti ==== Slavery in Haiti began at an unknown time with slavery being already practiced by the native populations when Christopher Columbus on the island in 1492. European colonists would go and institutionalize slavery on the island and turn it into a major business which was devastating to the native population. Following the indigenous Taíno's near decimation from forced labour, disease and war, the Spanish, under advisement of the Catholic priest Bartolomé de las Casas, and with the blessing of the Catholic church, who also wished to protect the indigenous people, began engaging in earnest in the use of African slaves. During the French colonial period beginning in 1625, the economy of Haiti (then known as Saint-Domingue) was based on slavery, and the practice there was regarded as the most brutal in the world.
== Method == Depending on where the bone graft is needed, a different doctor may be requested to do the surgery. Doctors and physicians that perform bone graft procedures are commonly orthopedic surgeons, otolaryngology head and neck surgeon, neurosurgeons, craniofacial surgeons, oral and maxillofacial surgeons, podiatric surgeons and periodontists, dental surgeons, oral surgeons and implantologists.
Sources: en.wikipedia.org
==== Handwritten notes ==== Police searches of Letby's home and her handbag recovered several handwritten notes containing statements including "I killed them on purpose because I'm not good enough to care for them", "I am evil I did this", but also phrases such as "I haven't done anything wrong". The prosecution characterised some of the phrases as incriminating, while the defence said they reflected emotional turmoil during employment disputes and the stress of being removed from clinical duties. Letby denied that the notes were a confession. Some criminology experts have since questioned the prosecution's interpretation, and The Guardian, relying on "sources close to the case", reported that the notes had been written on her GP's advice as a coping mechanism. The suggestion that writing the notes had been advised as part of counselling was not mentioned by Letby's appeal application.
=== Contestants === 1st-Hollie Fraser, Bakery Owner from Port Moody, British Columbia 2/3rd-James Cox, Bakery Owner and Pastry Chef from Chicago, Illinois 2/3rd-Ryan McCord, Pastry Chef from Nashville, Tennessee 4th-Stacy Day, Pastry Chef from Nashville, Tennessee 5th-Christa Aylward, Bakery Owner from Dublin, Ohio 6th-Mandi Del Toro, Home Baker from San Antonio, Texas 7/8th-Shefali Patel, Home Baker from Coppell, Texas 7/8th-Dan Pivovar, Pastry Chef from Onalaska, Wisconsin 9th-Adesuwa Elaiho, Bakery Owner from San Antonio, Texas 10th-Phoebe Martinson, Bakery Owner from Olympia, Washington 11th-Chad Conklin, Culinary Instructor from Dayton, Ohio 12th-Mike Yu, Restaurant Owner from Napa, California
=== Sports === Outback Steakhouse was the title sponsor of the Outback Champions Series tennis events and NCAA football's Outback Bowl. The sponsorship lasted through 2020. Outback is also a partner of the Tampa Bay Lightning and has a concession stand in Amalie Arena.
==== 11S ==== 20S proteasomes can also associate with a second type of regulatory particle, the 11S regulatory particle, a heptameric structure that does not contain any ATPases and can promote the degradation of short peptides but not of complete proteins. It is presumed that this is because the complex cannot unfold larger substrates. This structure is also known as PA28, REG, or PA26. The mechanisms by which it binds to the core particle through the C-terminal tails of its subunits and induces α-ring conformational changes to open the 20S gate suggest a similar mechanism for the 19S particle. The expression of the 11S particle is induced by interferon gamma and is responsible, in conjunction with the immunoproteasome β subunits, for the generation of peptides that bind to the major histocompatibility complex.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.